Category Archives: Molecular Medicine

Express News Service

NEW DELHI: BA.5, the new fast-moving Omicron sub-variant, fuelling widespread Covid-19 wave globally, is not expanding or spiking hospitalisation rate in India so far.

According to the US Centers for Disease Control and Prevention (CDC), an estimated 65 percent of coronavirus variants in the US last week were of the fast-spreading BA.5 sub-lineage.

Good at evading past immune protection from vaccination or earlier infection, BA.4 and BA.5 were first identified in March, and the World Health Organisation (WHO) started tracking them in April. By May-June, this most transmissible sub-variant took over the world and caused spikes in countries like South Africa, the UK, Europe and Australia.

However, in India, the sub-variant along with BA.4 has not caused a spike or increase in hospitalisation rate, the way it dominates globally.

Speaking with this newspaper, Dr N K Arora, head of the Covid-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI), said in India, the BA.2 variant is still dominant.

In India, BA.2 is still 85 percent. BA.4 and BA.5 are not expanding the way it is happening worldwide. The two Omicron sub-variants are less than 10 percent in the country, he said.

In May, India reported its first BA.5 in Telangana when an 80-year-old man in Hyderabad tested positive for the sub-variant, as per the Indian SARS-COV-2 Genomics Consortium (INSACOG). The octogenarian was fully vaccinated.

What is worrying is that, like the Delta variant, which created havoc in India and other parts of the world, BA.5 also affects the lungs. Earlier, Omicron was described as mild with symptoms of cold or flu.

BA.5 is different, according to a study published in medRxiv, a Yale and British Medical Journal that publishes studies not yet certified by peer review. The study said that the sub-variant is shifting back to the lower respiratory tract - at least in animal models, with a potential increase in disease severity and infection within lung tissue.

The researchers referenced another May preprint study that found BA.5 and close relative BA.4 replicate more efficiently in the alveoli of human lungs than so-called stealth Omicron, BA.2.

BA.5 not only gives the virus greater antibody evasion potential but concurrently has changed [where it tends to accumulate], along with an increased transmission potential in the community, Australias Kirby Institute authors said.

As BA.5 can infect cells more like Delta than the previous Omicron family of variants, a top US scientist has referred to the new sub-variant as Deltacron - a Delta-Omicron hybrid.

According to Dr Eric Topol, a professor of molecular medicine at Scripps Research and founder and director of the Scripps Research Translational Institute, the term Deltacron is more appropriate for BA.5, even though the subvariant isnt a true hybrid.

The technical lead on Covid-19, Maria Van Kerkhove, has also said that "BA.5 has a growth advantage over the other sublineages of Omicron that are circulating.

However, she said there is no evidence that BA.5 is more dangerous than other Omicron variants. But stressed that spikes in cases could put health services under pressure and risk more people getting long Covid.

Original post:
BA.5 fuelling Covid wave globally, but the Omicron sub-variant is less than 10 percent in India - The New Indian Express

Friday, July 15, 2022

A diagnostic panel developed by researchers in Purdue Universitys College of Veterinary Medicine will enable its Animal Disease Diagnostic Laboratory (ADDL) to screen for 22 different vector-borne pathogens in a single test. The panel, designed to be used on cats and dogs, is the only test of its kind and will soon be available to clients of the ADDL.

Dr. Becky Wilkes, associate professor of molecular diagnostics in the colleges Department of Comparative Pathobiology, and head of the ADDLs Molecular and Virology sections, developed the methodology using next generation sequencing (NGS), a process that can sequence large amounts of DNA more economically than other techniques. First commercially available in the mid-2000s, NGS technology has been used to sequence the human genome and track foodborne outbreaks and infectious disease transmission.

Dr. Wilkes novel approach of incorporating NGS as an everyday diagnostic tool will facilitate more accurate identification of a wider range of pathogens in a single test through rapid sequencing of the pathogens DNA. Polymerase chain reaction testing (PCR), the current industry standard, can only test for three or four pathogens at a time in a single test and it only gives a fluorescent signal that pathogens are detected; it cannot sequence their DNA.

Were using a targeted NGS method to specifically identify vector-borne pathogens such as those transmitted through the bite of a mosquito, flea or tick, Dr. Wilkes said. Multiple pathogens can be found within the same tick and sometimes co-infections go undiagnosed because were not looking for all the organisms that could be there.

Diagnosing vector-borne diseases in dogs can be difficult because there are many different disease-causing agents that can be transmitted from an insect bite and the clinical signs caused by these agents often overlap. Patients can also initially present with non-specific signs, such as fever and lethargy.

For the NGS panel, Dr. Wilkes developed specific primers short single-stranded DNA fragments for each organism of interest, ensuring the primers would be specific for each pathogen. She then collaborated with Thermo Fisher Scientific to finalize the assay design, ensuring the primers wouldnt interact with each other or amplify genetic material from the dog or cat.

The primers target specific DNA segments in the pathogens of interest. This results in amplification of these pathogen-specific sequences if present in the sample. When pathogens are present, they make up less than 1% of the sample. The majority of the sample is made up of host genetic materials. NGS provides sequences for everything in the sample, including pathogens and the host genetic materials. The targeted NGS approach enhances the sequences of the pathogens of interest to make them easier to detect. Once the targeted DNA is sequenced, it can be compared to information in the GenBank database, an annotated collection of all publicly available DNA sequences, to confirm its identification as a pathogen.

As I researched NGS, I was amazed by the amount of data it generates, Dr. Wilkes said. In the past, you could only sequence one piece of DNA at a time, which could be 1,000 base pairs. Thats the process originally used to sequence the human genome. It took 13 years and $3 billion. With NGS, you can generate the same information in a matter of days. Its use as a diagnostic tool for pathogen detection was untested when I started working with targeted NGS. That motivated me to conduct this research to see if NGS could be used to create a targeted diagnostic panel that would be affordable for the veterinary community.

In a recent canine necropsy case at the Purdue Small Animal Hospital, Dr. Viju Pillai, a resident in anatomic pathology, suspected the dog had been infected with Rocky Mountain spotted fever, a relatively rare tick-borne zoonotic disease caused by the bacterium Rickettsia ricketsii. The ADDL doesnt have a standalone PCR for that organism and previously would not have been able to conduct a test onsite. A sample would have been sent out for PCR testing at another lab.

The NGS panel developed by Dr. Wilkes confirmed Dr. Pillais suspicion that the case was Rocky Mountain spotted fever. As the panel becomes more widely used, faster diagnosis of less common diseases will aid veterinarians in developing appropriate treatment plans for their patients.

Most tick-borne diseases are bacterial and can be treated with doxycycline, Dr. Wilkes said. But there are a few vector-borne diseases that are caused by parasites, and in those cases doxycycline wouldnt work. These organisms are less commonly tested for, and if they are missed it can delay proper treatment.

Earlier diagnosis and treatment is especially critical when the animal is infected with a zoonotic disease one that can spread to humans such as West Nile virus, Lyme disease, Rocky Mountain spotted fever or malaria. Although the initial panel targets vector-borne pathogens in cats and dogs, NGS technology can be applied to panels for a range of illnesses affecting a variety of species.

The method were launching is going to change the way we do diagnostics, said Dr. Kenitra Hendrix, director of the ADDL and clinical associate professor of veterinary diagnostic microbiology. We will no longer be limited to picking and choosing a few pathogens to determine whether or not they are present in the sample. Well be able to select these panels based on the syndrome the animal has which will give us a better understanding of all the potential causes of the disease.

Last year, the ADDL conducted 107,332 tests. Implementation of the NGS testing platform, which requires state-of-the-art equipment and specific lab expertise, will expand the ADDLs ability to fulfill its mission of providing accurate and reliable animal diagnostic services and consultations to its clients, which include veterinarians, animal health officials, livestock producers and animal owners. Future panels might be developed for diseases that spread through livestock, such as pigs and poultry.

Its a lengthy and expensive process to validate the panels, Dr. Hendrix said. So we need to be strategic about implementing tests that will be most useful to our clients, but the opportunities are limitless. Dr. Wilkes is a leading expert in molecular diagnostics for infectious diseases for animals. We are very fortunate to have her here at Purdue developing these diagnostic panels.

The research was funded by the American Kennel Club (AKC) Canine Health Foundation, which awarded Dr. Wilkes a $103,000 grant to develop the comprehensive vector-borne targeted NGS panel. Dr. Jobin Kattoor, postdoctoral research associate in the Department of Comparative Pathobiology, assisted Dr. Wilkes in validating the vector-borne panel. Through parallel sequencing, the panel will incorporate testing for additional infectious diseases that may cause gastrointestinal, respiratory, reproductive, dermatologic, or neurological signs in dogs and cats.

Dr. Wilkes was recently invited to present her research at a meeting of the Flat-Coated Retriever Society of America whose members were amazed at the number of organisms that can be detected with a single test.

The vector-borne testing is only part of this panel, Dr. Wilkes said. The panel is validated for 22 vector-borne pathogens, but it contains many more. It is capable of detecting basically all known pathogens in dogs and cats. That is what we are working toward.

Click here for more information about the comprehensive vector-borne targeted NGS panel.

Writer(s): Kat Braz | pvmnews@purdue.edu

Originally posted here:
Purdue's first-of-its-kind vector-borne disease panel screens for 22 different pathogens in a single test - Purdue University

Medical students around the country start their journey to become physicians by studying the human body in gross anatomy labs, where they are reminded that real people volunteered their bodies to serve as educational tools to train them to help others.

Its no different at the University of Arizona Colleges of Medicine Tucson and Phoenix. The Tucson-based Willed Body Program annually accepts 150-200 whole body donations, which are embalmed and put in cold storage for use by both colleges for up to two years. Afterward, the remains are cremated and ashes returned to the families or spread in nearby mountains.

The people of Arizona are incredibly generous in this respect, because I know some willed body programs do have issues with not enough donors. And we never do, said Jean Wilson, PhD, program director, anatomy instructor, professor of cellular and molecular medicine, and BIO5 Institute member. We always have enough every year to supply the needs of the college and beyond.

The Willed Body Program serves more than just the Colleges of Medicine Tucson and Phoenix. It also supplies bodies for the A.T. Still University School of Osteopathic Medicine in Phoenix and nursing programs at the UArizona College of Nursing, Arizona State University and Northern Arizona University.

Currently, about 9,000 Arizonans have been issued willed body donor cards through the program that was founded in 1967.

Dr. Wilson credits the programs success in large part to the respectful, professional tone set by its funeral directors, Jared and Kat Alvarado. The husband-and-wife team work with donors, the families, faculty, physicians, nurses, students and others who benefit from the program.

Theyre unbelievable, Dr. Wilson said of the Alvarados. In the 32 years Ive been affiliated with the program, weve had people who are fine. But between the two of them, Kat and Jared are exceptional. Theyre so good with the donor families and the donors. They know exactly the right things to say. Theyre very gentle and empathetic. We are super lucky to have them.

Jared has been with the program 12 years, and Kat for seven. Both hold associates degrees in mortuary science and served three-year apprenticeships before being licensed as morticians.

Ive worked at places without an in-house willed body program, where you deal with a third party, said James Proffitt, PhD, College of Medicine Tucson lead instructor for the gross anatomy lab and cellular and molecular medicine assistant professor. Having two trained funeral directors and morticians people who really understand the process of grief and dying makes this so much more community oriented, humanistic, engaging and empathetic with what donors and students need.

I take the same approach as if I were at a funeral home, but feelings surrounding death are slightly less intense. The donors who participate in the Willed Body Program want to be here and most express their excitement at being able to contribute to medical education.Kat Alvarado, UArizona Willed Body Program funeral director, embalmer and coordinator

The donor families are very used to working with Kat and Jared, Dr. Proffitt said. They understand their best interests are looked out for by those two. It creates this kind of community, this family of donors. And this is something I try to impress on our students. These donors arent people from somewhere else. Theyre Arizonans. Theyre our neighbors.

Kat said her interest in the field was piqued in college, when she worked as a funeral home service attendant. She later served as an embalmer, cremationist and funeral director for a funeral home.

At UArizona, she said, I take the same approach as if I were at a funeral home, but feelings surrounding death are slightly less intense. The donors who participate in the Willed Body Program want to be here and most express their excitement at being able to contribute to medical education.

Unlike his wife, Jared said he sort of fell into his career as a funeral director.

After he graduated from high school, he took a job answering the phone at a funeral home. He started working with decedents his second day on the job. He went to mortuary school in Dallas, apprenticed in Texas and Arizona, and served as a crematory operator and embalmer before joining the Willed Body Program.

Death is hard on the families. But, at the same time, its great to hear how proud they are of their loved one donating their body to students for education, Jared said of what families say when he and Kat pick up a donated body. They hear similar comments at an annual willed body ceremony that offers donor families a chance to honor their loved ones.

Nearly 400 people attended the Willed Body Memorial Service in March. Among the speakers were the Alvarados, Dr. Wilson and medical students who expressed their gratitude for the donors beautiful and lasting gift to help them better learn their craft.

Jared does outreach to local high schools, talking to students about his experiences while encouraging others to follow in his footsteps.

My outreach to youth is important to me, he said. I wish I had someone who came to my high school to speak about these types of professions. Its my way of helping out as best I can.

The Alvarados are more than morticians. They also help fulfill continuing education needs for faculty physicians and nurses. In 2015, Jared Alvarado won the College of Medicine Tucsons Appointed Personnel Lura Hanekamp Award of Excellence for the part he plays in education for students, physicians and health professionals.

In 2019, Kat won a UArizona Individual Award for Excellence for her dedication to handling the programs administrative needs as Willed Body Program coordinator.

Jared also helps write academic papers related to the program, including a 2019 article on donor bodies used for students teaching students as a novel solution to time demands on doctors.

The program also hosts training opportunities for other medical professionals where staff need to understand human anatomy, including paramedics, emergency medical technicians and military health personnel. Jared assists in some training, including non-UArizona instruction for Davis-Monthan Air Force Base staff.

It usually is just myself and their instructors, so Im able to show them techniques and things Ive learned as part of the College of Medicine, he said.

Both are on call 24/7 to ensure the Willed Body Programs ongoing success, whether that involves working with instructors to help design specific training or traveling across the state to pick up donor bodies from a family or funeral home.

Thats important, Dr. Proffitt said, because donors bodies are the canvas upon which students and trainees learn to practice their art as healers. Without them, there is no healers art.

Read the original post:
Married Couple are 'Heart and Soul' of Willed Body Program - University of Arizona

Caris Life Sciences announced this week that it will be broadening its partnership with Epic, integrating its molecular testing portfolio with Epic's Orders and Results Anywhere network.

WHY IT MATTERSCaris offers whole exome and whole transcriptome sequencing, and by applying AI modeling to its clinico-genomic database, it can help researchers gain better insights into the molecular complexity of disease.

The new project builds on the existing integration of Caris' Genomics Module within Epicand will expand capabilities by offering easier ordering and receipt of molecular profiling results directly in patients' electronic health records.

Officials say Caris' whole suite of molecular profile services for tissue and blood samples will be available within the Orders and Results Anywhere network.

ORA network integration, expected to be available later this year, will help drive data-driven decision-making for Epic customers which represent 60% of oncologists nationwide, the companies note. By putting ordering and results directly into the network, Caris says it aims to offer more streamlined access to structured genomic data within the Epic environment.

THE LARGER TRENDThis is just the most recent in a string of announcements involving Epic and precision medicine technology developers. In June, Myriad Genetics announced it was working to integrate its genetic testing services within Epic's EHR workflows offering providers genetic insights for more personalized care and giving patients easier access to test results within MyChart.

In April, Guardant Health, which develops precision oncology tools,announced its own collaboration with Epic to streamline clinicians' ability to order Guardant blood tests, liquid biopsies and more within the EHR.

And this past August, Foundation Medicine announced a deal with Epic toadd its genomic profiling and testing services to the EHR workflow.

In other Epic news, the vendor announced this past month that it would join the Trusted Exchange Framework and Common Agreement and apply to connect to TEFCA as an inaugural Qualified Health Information Network.

ON THE RECORD"Caris Life Sciences is committed to fulfilling our organizational promise of making personalized precision medicine accessible to as many physicians and patients as possible," David Spetzler, president and CEO of Caris, said in a statement. "Building on the success of our Epic Genomics Module integration, ORA will further enhance patient access to critical molecular results they need to fight, and hopefully beat, cancer."

Alan Hutchison, VP of population health at Epic, said, "We are excited for this enhanced partnership with Caris to further increase health access and care, and the opportunity to help deliver precision medicine to a greater number of communities."

Twitter:@MikeMiliardHITNEmail the writer:mike.miliard@himssmedia.comHealthcare IT News is a HIMSS publication.

More here:
Epic, Caris Life Sciences working together on molecular testing integration - Healthcare IT News

Newswise A multi-disciplinary, One Health approach to cancer research is necessary to guide society in reduction of toxic substances, as well as regulation of chemical impacts on the environment and public health, according to an editorial published recently in Issue II of Annals of Research in Oncology.

This medical-scientific journal is published by Editor in Chief Professor Antonio Giordano, M.D., Ph.D., Director and Founder of Sbarro Institute for Cancer Research and Molecular Medicine, and the Sbarro Health Research Organization (SHRO), at Temple University. The editorial by Prof. Philip Landrigan, Director of the Global Public Health Programme, highlights the relationship between environmental issues and childhood cancer cases, which have been growing rapidly over the past 50 years.

Landrigan's editorial moves towards the new scientific paradigm known as One Health, by which is meant the indissoluble intertwining of three factors: human health, animal health and environmental health as interconnected and dependent on each other.

In particular, Landrigan emphasises the link between environment and cancer in paediatric subjects, underlining the lack of scientific models that consider the use of chemicals with undesirable effects on human health, which are not carefully studied, and the consequent increase in oncological cases in paediatrics. In fact, there is evidence that environmental exposure, in particular to manufactured chemicals, are a major cause of childhood cancer. The National Cancer Institute currently directs about 1% of its funding towards research into environmental causes of paediatric cancers.

Landrigan's hope is to identify new scientific models based on epidemiological and toxicological studies to address the rising incidence of childhood cancer, a major challenge for society and the cancer and public health communities.

Original post:
One Health Approach Is Necessary to Address Rising Environmental Causes of Childhood Cancers - Newswise

(Precision Vaccinations)

As of early July 2022, uncertainty persists as SARS-CoV-2 coronavirus mutations continue emerging. According to the World Health Organization, the Omicron BA.x variants are now dominant worldwide.

There is a clear need for strategies to tackle emerging variants and protect populations against potential future threats to human health, says vaccine researchers from the University of Oxford and Caltech.

A new consortium announced on June 5, 2022, aims to address these issues by establishing the first-in-human clinical proof of concept for a new vaccine design.

The consortium brings together researchers from the University of Oxford and Caltech to collaborate with deep tech innovation organization CPI and industrial biotechnology company Ingenza Ltd (Caltech-CPI-Oxford-Ingenza).

The Coalition for Epidemic Preparedness Innovations (CEPI) will partner with the consortium and has announced up to US $30 million to fund pre-clinical studies, GMP manufacturing, and Phase 1 trial based on this technology.

The vaccine will target both SARS-CoV-2 and several related bat viruses which have the potential to spread to humans. It builds on technologies developed by the Molecular Immunology Group at the University of Oxford and by the Bjorkman Group based at Caltech led by Professor Alain Townsend at the MRC Human Immunology Unit and Professor Pamela Bjorkman, respectively.

In contrast to many existing vaccine designs that use mRNA or a viral vector to present sections of the spike protein of a single type of virus to the immune system, this new vaccine will use protein nanoparticles containing a protein glue to attach related antigenic sections of the spike proteins from eight different viruses. By incorporating a mosaic-8 vaccine design created at Caltech, these nanoparticles would favor immune responses to the shared parts of each type of coronaviruses within a single vaccine.

Evidence published today in Science by the researchers demonstrates that this vaccine technology elicits protective immune responses against SARS-like viruses but also against some coronaviruses not presented in the trial vaccine. This suggests that the technology could protect against future novel SARS-CoV-2 variants and as-yet-undiscovered coronaviruses with the potential to spill over from animal populations.

Alain Townsend, Oxford Lead of the consortium, Professor of Molecular Immunology at the MRC Weatherall Institute of Molecular Medicine, University of Oxford, said:

The evolution of this consortium is an example of collaborative science at its best. We had been deeply impressed by the power of the glue for sticking proteins together developed by Mark Howarth (Biochemistry Oxford) and derived from his beautiful basic science investigations of the Streptococcus pyogenes bacterium.'

Together, we used this technology to make a prototype nanoparticle SARS-CoV-2 vaccine that induced highly potent responses in preclinical studies.'

Through connections made by Ian Wilkinson (Absolute Antibody), we joined with colleagues at Ingenza and CPI who succeeded in making a fully functional version of the vaccine produced in microbes, thus reducing the cost of production. In addition, we have been collaborating with Prof. Pamela Bjorkman and the Caltech team, who had independently developed the brilliant concept of the mosaic version of the vaccine and are excited to continue working with this world-class consortium.

The consortium partners are committed to equitable access to the project's outputs.

Dr. Jack Tan, Project Manager (Oxford) of the consortium, Senior Postdoctoral Scientist at the MRC Weatherall Institute of Molecular Medicine, said:

We are delighted to work with CEPI to further this nanoparticle technology to produce efficacious, low-cost, infrastructure-independent vaccine that will be accessible to low- and middle-income countries.

Dr. Richard Hatchett, CEO of CEPI, commented in a press release issued on July 6, 2022, There have already been three serious coronavirus epidemics or pandemics in the 21st century and COVID-19 continues to have a devastating impact on the worlds health, society, and economy. Creating vaccines that could provide broad protection against emerging COVID-19 variants and future coronavirus threats would not only help mitigate the damaging effects of another COVID-19-like pandemic, but it could also help reduce the time taken and funding spent continually updating vaccine formulations.

Thats why we are delighted to partner with this CPI-led research consortium to build on Wellcome Leaps initial investment to further advance this pioneering mosaic nanoparticle vaccine technology that, if successful, could work towards consigning the threat posed by coronaviruses to the history books.

The consortium aims to commence a Phase 1 trial in 2024, led by the Oxford Vaccine Group.

PrecisionVaccinationspublishes fact-checked, research-based news curated for mobile readership.

Read the original:
$30 Million Funding Empowers All-in-One Vaccine Candidate to Tackle Future Coronaviruses - Precision Vaccinations

LAUSANNE, Switzerland & SAN FRANCISCO--(BUSINESS WIRE)--Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed journal Aging Cell published new pre-clinical results showing the joint health benefits of gut microbiome postbiotic Urolithin A (UA). This is the first time a compound has been shown to improve mitochondrial health in an experimental model of osteoarthritis (OA).

This study showed that treatment with Amazentis proprietary Urolithin A, Mitopure, significantly improved mitochondrial health in human cartilage cells taken from both healthy and OA knee joints. And it showed that supplementation with Mitopure for eight weeks protected against osteoarthritis disease progression in an experimental model.

These findings highlight Mitopures benefits for joint and mitochondrial health. Mitopure works by supporting the cells ability to renew their powerplants, the mitochondria, during the aging process. This change is associated with age-related problems in various tissues, including osteoarthritis.

Previous research has shown Mitopure can improve mitochondrial health and muscle function in both older and middle-aged human populations. This new paper extends these benefits to cells in key joints such as the knee. Osteoarthritis is the most common age-related joint disorder, characterized by degradation of cartilage and other tissues, severe pain, and impaired mobility.

There are currently no effective solutions to treat osteoarthritis, a condition that is painful and limits the mobility of hundreds of millions of older people around the world. We tested Urolithin A in preclinical models of osteoarthritis and showed it has potential to both reduce inflammation and improve mitochondrial health, suggesting it may be a promising solution to support joint health and quality of life during aging, says Martin Lotz MD, lead author on the paper and Professor of Molecular Medicine at Scripps Research in California, USA.

This study is important and exciting as it shows, for the first time, that Urolithin A can increase mitochondrial health in living joint tissue, says Davide DAmico, first author on the paper and R&D Group Leader with Amazentis. It highlights the important role of mitophagy in maintaining healthy functioning joints throughout life.

In this study, Mitopure showed two key beneficial effects on cartilage cells from both healthy donors and OA patients:

The second part of the study focused on the effect of supplementing Mitopure for 2 months on an experimental pre-clinical model of osteoarthritis. This model mimics the same symptoms experienced by people suffering from osteoarthritis, i.e. progressive cartilage damage, increased pain and inflammation.

"It was great to collaborate with Scripps Research to expand the body of evidence on the health applications of Urolithin A into joint health. Its exciting to see a compound and mechanism of action that is benefiting both muscle and joints. We remain committed to delivering products that are clinically proven to have a meaningful impact on peoples health says Chris Rinsch, CEO and co-founder of Amazentis.

The new results are significant because they add to growing evidence of the benefits of Mitopure on age-related conditions. Recent studies showed that Mitopure can improve mitochondrial health and counteract age-related muscle function decline in both healthy elderly and middle-aged overweight subjects. Together, the latest research supports a combined beneficial action of Urolithin A in both muscle and joints.

Doi: 10.1111/acel.13662

About AmazentisAmazentis is an innovative life sciences company employing todays leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure Urolithin A in top peer reviewed scientific journals including Nature Medicine (doi:10.1038/nm.4132), Nature Metabolism (doi: 10.1038/s42255-019-0073-4), JAMA Network Open (doi:10.1001/jamanetworkopen.2021.44279), Cell Reports Medicine (Doi: 10.1016/j.xcrm.2022.100633) and European Journal of Clinical Nutrition (https://doi.org/10.1038/s41430-021-00950-1). The company has a global strategic partnership with Nestl Health Science to expand the health applications of Mitopure linked to mitochondrial and cellular health. For more information on Amazentis, please visit http://www.amazentis.com.

About MitopureMitopure is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit http://www.mitopure.com.

About TimelineTimeline is brought to you by the inventors of Mitopure. This novel, science-first nutrition brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of clinically validated nutritional products to optimize cellular health. For more information, please visit http://www.timelinenutrition.com.

Related Linkshttps://www.amazentis.com

The rest is here:
New Study shows Urolithin A (Mitopure) Improves Mitochondrial Health, Reduces Joint Cartilage Damage and Alleviates Pain in Osteoarthritis - Business...

STOCKHOLM, July 7, 2022 /PRNewswire/ --The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA, in which the diabetes vaccine Diamydwas administered directly into the lymph node of 14 patients aged 30 to 70 years with the autoimmune form of diabetes called LADA (Latent Autoimmune Diabetes in Adults). Analyses also showed a positive immunological response to the treatment and the clinical course appears promising with all individuals remaining insulin-independent 12 months after treatment.

"These results are very encouraging and the next step is together with collaborators and authorities evaluate the regulatory requirements to get the diabetes vaccine Diamyd approved as a disease-modifying therapy in individuals diagnosed with LADA", says Ulf Hannelius, CEO of Diamyd Medical.

All patients in the trial were followed for twelve months after their first injection. The topline results showed that the safety was good with no treatment-related severe adverse events. The treatment was well tolerated by the trial participants, all of whom completed the study with no drop-outs. The immunological analyses showed a similar response to the treatment as has been shown in previous trials in individuals with recent-onset type 1 diabetes, with a clear GAD-specific immune response evident in both circulating antibodies and cell-based reactions.

The clinical course appears positive with all 14 individuals remaining insulin-independent after 12 months of follow-up. The endogenous insulin production, measured as mixed-meal stimulated C-peptide, declined on average only 10% over 12 months.

"The GADinLADA trial has been successful, and treatment with three intralymphatic injections of Diamyd has been well received by the LADA patients," says PhD Ingrid K Hals, Sponsor's representative of the trial. "We will present the results from this trial at the upcoming international Europen Association for the Study of Diabetes (EASD) conference in Stockholm in September and we look forward to evaluating together with Diamyd Medical the next steps to make this important treatment available for individuals diagnosed with LADA."

Of the 14 LADA patients included in the trial, half carry the HLA haplotype DR3-DQ2 that is associated with a positive clinical response to Diamyd treatment in individuals recently diagnosed with type 1 diabetes. For the 7 individuals carrying HLA DR3-DQ2, endogenous insulin production (stimulated C-peptide) decreased on average by 8 % over the 12 month study period, while in the 7 individuals not carrying HLA DR3-DQ2, it declined by 13 %. GAD-stimulated cell proliferation showed a decrease in proliferation between 5 and 12 months for the HLA-DR3-DQ2 group while a comparable decrease was not observed for the group negative for HLA DR3-DQ2, reflecting the patterns seen in recent-onset type 1 diabetes.

The results will be presented at the upcoming EASD conference to be held in Stockholm on September 19-23, 2022. The accepted abstract is entitled "Early effects of treatment with intralymphatic administration of rhGAD65 in LADA appear similar to those observed in type 1 diabetes", and will be presented as an oral abstract on September 20, 2022, as part of the session "OP 10 Beta cells: protecting what is precious".

About the GADinLADA trialThe main aim of the trial was to evaluate the safety of three intralymphatic injections of Diamyd in patients with LADA (Latent Autoimmune Diabetes in Adults). The patients were recruited in Norway at the Norwegian University of Science and Technology (NTNU), Dept. of Clinical and Molecular Medicine, in Trondheim, in collaboration with St. Olavs Hospital, University Hospital in Trondheim, and in Sweden at the Center for Diabetes, Akademiskt specialistcentrum, an academic specialist unit run in collaboration between Stockholm County's healthcare area, Karolinska Institutet and Karolinska University Hospital. The patients included in the trial were between 30 and 70 years old, diagnosed with LADA within the last 18 months and were not yet on insulin therapy. The Sponsor of the trial has been the Norwegian University of Science and Technology with Ingrid K Hals, PhD, as Sponsor's representative. Diamyd Medical has contributed with study drugs, expertise and some financial support for immunological analyses and determination of HLA haplotypes.

About LADALatent Autoimmune Diabetes in Adults represents close to 10% of patients diagnosed with type 2 diabetes. LADA is characterized by an ongoing autoimmune destruction of the insulin-producing beta cells, a process similar to that of type 1 diabetes, but slower. Although research categorizes LADA as autoimmune diabetes, the disease is still in most cases treated according to the guidelines for type 2 diabetes. LADA patients are usually not insulin dependent at diagnosis, but for most patients, insulin therapy is required within a few years of diagnosis.

About Diamyd MedicalDiamyd Medical develops precision medicine therapies for Type 1 Diabetes. The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company's European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. DIAGNODE-3, a confirmatory Phase III trial is on-going. A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd. Diamyd Medical also develops the GABA-based investigational drug Remygen as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen trial in individuals living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser; phone: +46 8-528 00 399, e-mail: [emailprotected]

For further information, please contact:Ulf Hannelius, President and CEOPhone: +46 736 35 42 41E-mail: [emailprotected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/diamyd-medical-ab/r/promising-topline-results-for-intralymphatic-diamyd--in-patients-with-lada,c3598517

The following files are available for download:

SOURCE Diamyd Medical AB

Read the rest here:
Promising topline results for intralymphatic Diamyd in patients with LADA - PR Newswire

Wilmington, Delaware, United States, Transparency Market Research Inc.: Transparency Market Research (TMR) has published a new report titled, Blood Group Typing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018 to 2026. According to the report, the global blood group typing market was valued at US$ 1,500.0 Mn in 2017 and is projected to reach US$ 3,556.0 Mn by 2026, expanding at a high CAGR of 10.3% from 2018 to 2026. Increase in blood transfusion rate across the world is anticipated to fuel the global blood group typing market during the forecast period.

North America and Europe are expected to dominate the global market during the forecast period. The market in these regions is primarily driven by the increase in government initiatives and a highly structured health care industry. The market in Europe is projected to expand at a high growth rate of 10.1% from 2018 to 2026. The market in Asia Pacific is expected to expand at a rapid pace during the forecast period. The market in Asia Pacific is anticipated to expand at a high CAGR of 10.7% from 2018 to 2026. The blood group typing market in Latin America is likely to expand at a moderate growth rate during the forecast period.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=48627

Increase in preference for PCR-based technique to boost market

In terms of technique, the PCR-based segment is projected to account for a dominant share of the global blood group typing market during the forecast period. The segment is anticipated to expand at a CAGR of 10.6% from 2018 to 2026. Dominance of the segment is attributed to the increasing preference for PCR-based technique because of rising incidence of major chronic diseases such as aplastic anemia, sickle cell anemia, leukemia, and traumatic injuries, resulting increase in blood transfusion rate in countries across the globe.

Additionally, increasing the usage of PCR-based technique in the detection of rare type of blood group is a key factor that is expected to fuel the segment. The microarray-based segment held a major share of the market, following the PCR-based segment, due to increasing awareness about this technique. Assay-based technique and massively parallel technique segments accounted for around 30.0% share of the global blood group typing market, in terms of revenue, in 2017.

Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=48627

Consumables segment dominates the market

The report offers detailed segmentation of the global blood group typing market based on product, technique, test, and end-user. In terms of product, the market has been classified into instrument (automated, semi-automated, and manual), consumables (reagent, test kits, antisera, others), and services. The consumables segment is estimated to hold a leading share of the global market during the forecast period. Higher share held by the segment is attributed to the constant development of new molecular diagnostic test kits and reagents, which reduces the turnaround time required for results, and increase in number of blood transfusions, globally, every year are key factors fueling the consumables segment.

Antibody screening test & ABO blood test: Top two test employed for blood group typing

In terms of test, the antibody screening test segment is projected to hold a dominant share of global blood group typing market by the end of the forecast period. The segment is likely to expand at a CAGR more than 10.0% between 2018 and 2026. Major factor responsible for the dominance of this segment is the rise in incidence of transfusion transmitted infections (TTIs), especially in lower-middle income and low-income countries. The ABO blood test segment held a major share, following the antibody screening test, due to increasing utilization of this test for blood grouping. HLA typing and antigen segments accounted for around 30.0% share of the global blood group typing market, in terms of revenue, in 2017.

Request for Analysis of COVID-19 Impact of Blood Group Typing Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=48627

Hospital segment to expand at significant CAGR

Based on end-user, the hospital segment accounted for a leading share of the global blood group typing market in 2017. It is projected to gain market share by the end of 2026. The segment is anticipated to expand at a CAGR of 10% during the forecast period due to the large patient population undergoing surgical procedures in hospitals requiring blood transfusion, and increasing emphasis on blood grouping and patient testing. Clinical laboratories was a prominent segment, following the hospital segment, of the market in 2017. This is due to the rise in number of clinical laboratories for blood grouping and screening. This, in turn, is likely to drive the clinical laboratories segment during the forecast period.

North America to be highly lucrative market for blood group typing market

The blood group typing market in North America is driven by high percentage of active and voluntary blood donors in the U.S. and Canada, increasing number of blood transfusions per year in the region, and various blood transfusion policies being implemented regarding safety and testing of blood for infectious diseases. This, in turn, is further boosting the demand for blood grouping instruments and kits and reagents in North America. Moreover, a large number of players in the U.S. are focusing on R&D in order to introduce new products. The U.S. is an early adopter of innovative products, as most pharmaceutical products are first launched in the country. This is likely to boost the market in the country in the near future.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=48627

Trend of strategic alliance with local companies to strengthen distribution network and expand geographic presence

The global blood group typing market is fragmented, owing to the presence of several small- and large-scale companies. However, the market is dominated by a few major players with strong global presence. The report provides profiles of leading players operating in the global blood group typing market. Key players in the market include Grifols, S. A., Bio-Rad Laboratories, Inc., Merck KGaA, Ortho Clinical Diagnostics, QUOTIENT LIMITED, BAG Health Care GmbH, Immucor, Inc., Beckman Coulter, Inc. (Danaher Corporation), Agena Bioscience, Inc., Rapid Labs Ltd, and Novacyt Group.

More Trending Reports by Transparency Market Research

Forensic Technologies Market: Forensic Technologies Market (Service: DNA Profiling [PCR, Y-STR, RFLP, Mitochondrial DNA, and Others]; Chemical Analysis [Mass Spectrometry, Chromatography, Spectroscopy, and Others]; Biometric/Fingerprint Analysis, Firearm Analysis, and Others; and Location: Laboratory Forensics [LIMS] and Portable Forensics [FaaS]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Microbiology Culture Market: Microbiology Culture Market (Type: Liquid Media and Plate Media; Culture Type: Bacterial Culture, Eukaryotic Culture, and Virus and Phage Culture; Media Type: Simple Media, Complex Media, Synthetic Media, Special Media, and Others; and Application: Food & Water Testing, Bioenergy & Agricultural Research, Cosmetic Industry, Pharmaceutical Industry, and Others) - U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Nanomedicine Market: Nanomedicine Market (Application: Cardiovascular, Anti-inflammatories, Anti-infectives, Neurology, Oncology, and Others [Dental, Orthopedic, Urology, and Ophthalmic]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Smart Medical Devices Market: Smart Medical Devices Market (Product Type: Diagnostic & Monitoring Devices, Therapeutic Devices, Injury Prevention & Rehabilitation Devices, and Others; Modality: Portable, Wearable, and Others; and End-user: Hospitals, Clinics, Home Care Settings, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Bioinformatics Market: Bioinformatics Market (Platforms, Tools, and Services: Platforms, Tools, and Services; and Application: Preventive Medicine, Molecular Medicine, Gene Therapy, Drug Development, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Taurine Market: Taurine Market (Type: Food Grade and Pharmaceutical Grade; Application: Health Care Products, Pet Food, Beverage, and Others; and Form: Tablets/Capsules, Liquid-based Serum, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Telehealth Market: Telehealth Market (Component: Hardware, Software, and Services; Application: Radiology, Cardiology, Urgent Care, Remote ICU, Psychiatry, Dermatology, and Others; and End-user: Payers, Providers, Patients, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Medical Device Technologies Market: Medical Device Technologies Market (Device Type: Cardiology Devices, Diagnostic Imaging Devices, Orthopedic Devices, Ophthalmology Devices, Endoscopy Devices, Diabetes Care Devices, Wound Management Devices, Kidney/Dialysis Devices, Anesthesia & Respiratory Care Devices, and Others; and End-user: Academics & Research, Hospitals, Clinics, Diagnostic Centers, Ambulatory Surgical Centers, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

Read more here:
Blood Group Typing Market: Increase in Blood Transfusion Rate Across the World to Drive the Market - BioSpace

Photo of Dr. Daniel Goldberg courtesy of Washington University

Dr. Daniel Goldberg, a professor of molecular microbiology at Washington University School of Medicine in St. Louis, recently received one of the highest honors bestowed in the science community: He was elected to the National Academy of Sciences, a nonprofit society of distinguished scholars to whose ranks their peers add scientists for outstanding research contributions.

Goldberg, the David M. and Paula L. Kipnis Distinguished Professor in the schools Division of Infectious Diseases, is internationally known for his work in advancing drug development for malaria treatments. By studying the basic biology of malaria parasites, he identified a group of proteins called plasmepsins that play a key role in the parasites ability to live inside red blood cells. He also identified several compounds that inhibit these plasmepsins and is exploring whether they can be developed as drugs.

What excites me most about my work is the scientific odyssey that I get to undertake with each of the really talented young people in the lab, Goldberg says. Sharing in their discoveries, as well as their scientific and personal development, is the greatest privilege of the job.

People are also reading

In addition to identifying new targets for antimalarial drug development, Goldberg and his team found a toxin that the malaria parasite puts out into the patients bloodstream to cause leaky blood vessels, which are a hallmark of severe malaria. We have figured out how this molecule works, which gives us a clear idea of how to treat these terrible malaria complications, he says. Malaria is a parasitic infection that kills over 600,000 people a year, mostly children in Africa. We desperately need new treatments.

Goldberg has served in many roles at the university, including as a past co-director of the Division of Infectious Diseases, as director of the medical scientist training program and as a member of the executive council of the Division of Biology and Biomedical Sciences, according to a university press release. He is a fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation and the American Association of Physicians. His many honors include the American Society for Biochemistry and Molecular Biologys prestigious C.C. and Alice Wang Award in Molecular Parasitology. He also was a Howard Hughes Medical Institute Investigator for 20 years.

Goldberg is one of 120 newly elected U.S. members of the National Academy of Sciences and the only Washington University faculty member elected to the academy this year. Im pleased that my scientific colleagues regard my work highly, he says. It gives Washington University more recognition as a great place to do scientific research.

Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, medicine.wustl.edu

Get local news delivered to your inbox!

See the rest here:
Professor at Washington University School of Medicine in St. Louis Elected to National Academy of Sciences - Ladue News